AIIMS unable to find required number of volunteers for phase 3 trial of Bharat Biotech’s Covid vaccine

The AIIMS here is unable to find the required number of volunteers for Bharat Biotech’s Phase 3 Covid-19 vaccine trial, with officials saying that people are unwilling to participate in the exercise thinking why to take part in a test when a vaccine would be available. soon for everyone.

The All India Institute of Medical Sciences (AIIMS) in the national capital is one of the sites conducting the final phase of the vaccine trial, “Covaxin,” and needs approximately 1,500 volunteers for the purpose.

Covaxin was developed in-house by Bharat Biotech, in collaboration with the Indian Council of Medical Research (ICMR).

“We wanted 1,500-2,000 participants, but so far we have only been able to recruit around 200 participants. People are not willing to participate in the exercise thinking about why they should take part in a trial when a vaccine will soon be available to everyone, “said Dr. Sanjay Rai, a professor in the department of community medicine at AIIMS and also the principal investigator of the study.

He said the volunteers decided to give up after the randomized double-blind placebo-controlled trial was explained to them, in which 50% would be given the injection while the other 50% would be given the placebo.

“People refuse to participate in the clinical trial after learning about the procedure, saying why take part in a trial when a vaccine is soon available,” said Dr. Rai.

He said when Phase 1 trial was due to begin, they needed 100 participants, but they received over 4,500 questions.

Even during Phase 2 of the trial, the hospital received around 4,000 applications.

Dr. Rai said people should come forward to participate in the trial and are planning to raise awareness through advertisements, emails and phone calls why it is important to take part in the clinical trial to get a safe and effective vaccine.

According to the “Covid-19 Vaccine Operational Guidelines”, which were recently issued in the United States by the Center, the Covid-19 vaccine will first be offered to healthcare professionals, frontline workers and those over 50 years of age. followed by those under 50 years of age with associated comorbidities, based on the evolution of the pandemic situation and, finally, the remaining population, based on the epidemiology of the disease and the availability of vaccines.

The priority group over the age of 50 can be further divided into those over the age of 60 and those between the ages of 50 and 60 for phasing in, based on the pandemic situation and the availability of vaccines.

“The latest electoral roll for the Lok Sabha and Legislative Assembly elections will be used to identify the population aged 50 or over,” the guidelines state.

In the first phase of vaccination, nearly 30 million people are expected to be vaccinated.

Twelve photo identification documents including voter ID, Aadhaar card, driver’s license, passport and retirement documents will be required for self-registration on the Co-WIN website.